Literature DB >> 27192991

Pneumolysin Mediates Platelet Activation In Vitro.

Jan Gert Nel1, Chrisna Durandt2, Timothy J Mitchell3, Charles Feldman4, Ronald Anderson2, Gregory R Tintinger5.   

Abstract

This study has explored the role of the pneumococcal toxin, pneumolysin (Ply), in activating human platelets. Following exposure to Ply (10-80 ng/ml), platelet activation and cytosolic Ca(2+) concentrations were measured flow cytometrically according to the level of expression of CD62P (P-selectin) and spectrofluorimetrically, respectively. Exposure to Ply resulted in marked upregulation of expression of platelet CD62P, achieving statistical significance at concentrations of 40 ng/ml and higher (P < 0.05), in the setting of increased influx of Ca(2+). These potentially pro-thrombotic actions of Ply were attenuated by depletion of Ca(2+) from the extracellular medium or by exposure of the cells to a pneumolysoid devoid of pore-forming activity. These findings are consistent with a mechanism of Ply-mediated platelet activation involving sub-lytic pore formation, Ca(2+) influx, and mobilization of CD62P-expressing α-granules, which, if operative in vivo, may contribute to the pathogenesis of associated acute lung and myocardial injury during invasive pneumococcal disease.

Entities:  

Keywords:  CD62P; Calcium; Community-acquired pneumonia; P-selectin; Pneumococcus; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2016        PMID: 27192991     DOI: 10.1007/s00408-016-9900-5

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  21 in total

Review 1.  Cardiac diseases complicating community-acquired pneumonia.

Authors:  Stefano Aliberti; Julio A Ramirez
Journal:  Curr Opin Infect Dis       Date:  2014-06       Impact factor: 4.915

2.  Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.

Authors:  Lea-Ann S Kirkham; Alison R Kerr; Gill R Douce; Gavin K Paterson; Deborah A Dilts; Dai-Fang Liu; Tim J Mitchell
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality.

Authors:  Vicente F Corrales-Medina; Daniel M Musher; George A Wells; Julio A Chirinos; Li Chen; Michael J Fine
Journal:  Circulation       Date:  2012-01-04       Impact factor: 29.690

4.  Pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae, does not require a thiol group for in vitro activity.

Authors:  F K Saunders; T J Mitchell; J A Walker; P W Andrew; G J Boulnois
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

5.  Characterization of the interactions of the pneumolysoid, Δ6 PLY, with human neutrophils in vitro.

Authors:  R Cockeran; H C Steel; A J Theron; T J Mitchell; C Feldman; R Anderson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

6.  Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes.

Authors:  Vicente F Corrales-Medina; Jose Serpa; Adriana M Rueda; Thomas P Giordano; Biykem Bozkurt; Mohammad Madjid; David Tweardy; Daniel M Musher
Journal:  Medicine (Baltimore)       Date:  2009-05       Impact factor: 1.889

7.  Platelet-neutrophil complex formation-a detailed in vitro analysis of murine and human blood samples.

Authors:  Maximilian Mauler; Julia Seyfert; David Haenel; Hannah Seeba; Janine Guenther; Daniela Stallmann; Claudia Schoenichen; Ingo Hilgendorf; Christoph Bode; Ingo Ahrens; Daniel Duerschmied
Journal:  J Leukoc Biol       Date:  2015-11-17       Impact factor: 4.962

8.  Persistence of pneumolysin in the cerebrospinal fluid of patients with pneumococcal meningitis is associated with mortality.

Authors:  Emma C Wall; Stephen B Gordon; Samia Hussain; Upali R S Goonetilleke; Jenna Gritzfeld; Matthew Scarborough; Aras Kadioglu
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

9.  Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection.

Authors:  Yasir Alhamdi; Daniel R Neill; Simon T Abrams; Hesham A Malak; Reham Yahya; Richard Barrett-Jolley; Guozheng Wang; Aras Kadioglu; Cheng-Hock Toh
Journal:  PLoS Pathog       Date:  2015-05-14       Impact factor: 6.823

10.  Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function.

Authors:  Armand O Brown; Beth Mann; Geli Gao; Jane S Hankins; Jessica Humann; Jonathan Giardina; Paola Faverio; Marcos I Restrepo; Ganesh V Halade; Eric M Mortensen; Merry L Lindsey; Martha Hanes; Kyle I Happel; Steve Nelson; Gregory J Bagby; Jose A Lorent; Pablo Cardinal; Rosario Granados; Andres Esteban; Claude J LeSaux; Elaine I Tuomanen; Carlos J Orihuela
Journal:  PLoS Pathog       Date:  2014-09-18       Impact factor: 6.823

View more
  19 in total

1.  Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro.

Authors:  Kristin Jahn; Stefan Handtke; Raghavendra Palankar; Sabrina Weißmüller; Geraldine Nouailles; Thomas P Kohler; Jan Wesche; Manfred Rohde; Corina Heinz; Axel F Aschenbrenner; Martina Wolff; Jörg Schüttrumpf; Martin Witzenrath; Sven Hammerschmidt; Andreas Greinacher
Journal:  Blood Adv       Date:  2020-12-22

Review 2.  Contribution of Human Thrombospondin-1 to the Pathogenesis of Gram-Positive Bacteria.

Authors:  Ulrike Binsker; Thomas P Kohler; Sven Hammerschmidt
Journal:  J Innate Immun       Date:  2019-02-27       Impact factor: 7.349

Review 3.  Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Vikash Jaiswal; Song Peng Ang; Kriti Lnu; Angela Ishak; Nishan Babu Pokhrel; Jia Ee Chia; Adrija Hajra; Monodeep Biswas; Andrija Matetic; Ravinder Dhatt; Mamas A Mamas
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

Review 4.  The Yin and Yang of Pneumolysin During Pneumococcal Infection.

Authors:  Joana M Pereira; Shuying Xu; John M Leong; Sandra Sousa
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 5.  Epidemiology, virulence factors and management of the pneumococcus.

Authors:  Charles Feldman; Ronald Anderson
Journal:  F1000Res       Date:  2016-09-14

Review 6.  Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Pneumonia (Nathan)       Date:  2016-07-21

7.  Replacing the 238th aspartic acid with an arginine impaired the oligomerization activity and inflammation-inducing property of pyolysin.

Authors:  Wenlong Zhang; Haili Wang; Bing Wang; Yue Zhang; Yunhao Hu; Bo Ma; Junwei Wang
Journal:  Virulence       Date:  2018       Impact factor: 5.882

8.  Epigallocatechin gallate inhibits Streptococcus pneumoniae virulence by simultaneously targeting pneumolysin and sortase A.

Authors:  Meng Song; Zihao Teng; Meng Li; Xiaodi Niu; Jianfeng Wang; Xuming Deng
Journal:  J Cell Mol Med       Date:  2017-04-12       Impact factor: 5.310

Review 9.  Pneumolysin: Pathogenesis and Therapeutic Target.

Authors:  Andrew T Nishimoto; Jason W Rosch; Elaine I Tuomanen
Journal:  Front Microbiol       Date:  2020-07-02       Impact factor: 5.640

Review 10.  Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia.

Authors:  Ronald Anderson; Jan G Nel; Charles Feldman
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.